Among these patients, GLP-1 medications were linked to: 39% fewer drug overdoses 26% fewer hospitalizations related to substance use 31% fewer emergency department visits 50% lower risk of drug-related deaths Researchers said the size and consistency of these results across multiple substances were surprising
Glutathione peroxidases and glutathione reductase activities during Bufo bufo development
People with diabetes should not use retatrutide outside a clinical trial
Projected approval window: late 2027 to 2028
OBESITY EXPERT REVEALS THE BEST WAY TO DECIDE IF GLP-1S ARE RIGHT FOR YOU The New England Journal of Medicine published results from a 2023 phase 2 retatrutide trial for obesity, revealing "substantial reductions in body weight" after 48 weeks of treatment
Maintaining a healthy weight is crucial for your dogs overall well-being, as obesity can lead to serious health issues such as joint problems, diabetes, heart disease, and more